Financial Performance - The company reported a significant increase in revenue for the first half of 2024, achieving a total of 500 million RMB, representing a 25% growth compared to the same period last year[1]. - The company reported a revenue of RMB 378.7 million for the first half of 2024, representing a year-on-year increase of 25%[10]. - The company's operating revenue for the first half of 2024 was approximately ¥418.24 million, a decrease of 16.61% compared to the same period last year[16]. - The net profit attributable to shareholders of the listed company was approximately -¥151.61 million, representing a decline of 535.56% year-on-year[16]. - The company reported a significant decrease in cash flow from operating activities, with a net cash outflow of -332,367,193.28 RMB, a 72.00% improvement from -1,187,043,919.45 RMB in the previous year[93]. - The total operating revenue for the first half of 2024 was RMB 418,235,233.09, a decrease of 16.6% compared to RMB 501,543,883.09 in the same period of 2023[151]. - The company's total comprehensive income for the first half of 2024 was a loss of ¥157,475,113.02, compared to a gain of ¥66,866,003.55 in the first half of 2023[153]. User Engagement and Market Expansion - User data indicates that the active user base has expanded to 1.2 million, marking a 15% increase year-over-year[1]. - User data indicated a 30% increase in the number of active users of the company's diagnostic products compared to the previous year[10]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by 2025[10]. - The company has expanded its market presence in Asia, achieving a 30% increase in market share in the region[37]. - The company reported a significant increase in user data, with a growth rate of 25% year-over-year in the first half of 2024[36]. Research and Development - The company is investing 100 million RMB in R&D for new technologies aimed at enhancing product efficiency and accuracy[1]. - The company is investing RMB 50 million in R&D for advanced diagnostic technologies over the next two years[10]. - Research and development expenses accounted for 34.98% of operating revenue, an increase of 10.31 percentage points compared to the previous year[17]. - R&D investment totaled ¥146,302,173.83, an increase of 18.23% compared to ¥123,739,625.87 from the previous year[73]. - The company has a comprehensive system for R&D, registration, procurement, production, and sales, ensuring operational efficiency and product innovation[42]. Product Development and Launches - New product launches in the diagnostics segment contributed to a 30% increase in sales volume during the first half of 2024[1]. - The company plans to launch three new diagnostic products by the end of 2024, focusing on molecular diagnostics and immunodiagnostics[10]. - The company has expanded its product line, launching 10 new diagnostic tests in the infectious disease segment[36]. - The company plans to introduce five new diagnostic products by the end of 2024, targeting both domestic and international markets[38]. - The company launched multiple new antibody reagents for immunohistochemistry, including AAT, CD57, and CDX-2, all classified as domestic Class I in vitro diagnostics, with a release date of January 15, 2024[49]. Strategic Initiatives and Acquisitions - The company is exploring potential acquisitions to enhance its product portfolio, with a focus on companies in the biotechnology sector[1]. - A strategic acquisition of a local biotech firm is expected to enhance the company's R&D capabilities and product offerings[10]. - The company has completed two strategic acquisitions in the last quarter, enhancing its product portfolio and market reach[36]. - The company completed acquisitions to strengthen its supply chain and market layout, including the acquisition of Confirm and Hangzhou Laihe, enhancing its capabilities in infectious disease and drug testing[84]. Market Trends and Industry Insights - The global IVD market size reached $106.26 billion in 2023, with an expected growth to $128 billion by 2028, reflecting a CAGR of approximately 3.8%[22]. - In 2023, the Chinese IVD market size was ¥125.3 billion, showing a year-on-year growth of 12.6%, and is projected to increase to ¥133.2 billion in 2024[26]. - The largest segment in the Chinese IVD market is immunodiagnostics, holding a 35% market share, followed by biochemical diagnostics at over 20%[26]. - The Asia-Pacific region is expected to have the highest CAGR in the global IVD market at around 4.4% from 2023 to 2028[24]. Financial Guidance and Future Outlook - The company has set a revenue guidance of 1.2 billion RMB for the full year 2024, reflecting an expected growth rate of 20%[1]. - Future guidance estimates a revenue growth of 20% for the second half of 2024, driven by market expansion and new product launches[10]. - Future outlook indicates a projected revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion[36]. - The company plans to continue focusing on R&D and market expansion strategies to improve future performance[17]. Risk Factors and Challenges - The company has identified key risk factors that may impact future performance, including regulatory changes and market competition[1]. - The company faces significant risks of potential losses in 2024 due to high management, R&D, and sales expenses from ongoing projects and acquisitions[86]. - The company is exposed to product development risks, particularly in the highly technical field of in vitro diagnostics, which requires substantial innovation and regulatory compliance[88]. - The company is navigating intense domestic market competition, influenced by large-scale procurement policies and price competition, which may hinder market expansion[90]. Environmental and Social Responsibility - The company has implemented carbon reduction measures, focusing on energy-saving management and optimizing production plans to reduce greenhouse gas emissions[114]. - The company has established an environmental management system in compliance with national laws and ISO14001 standards, enhancing employee awareness of environmental protection[113]. - The company has not experienced any environmental violations or received penalties from environmental authorities during the reporting period[112]. Shareholder and Corporate Governance - The board has confirmed that there are no non-operational fund usages by controlling shareholders or related parties[1]. - The company has committed to maintaining strict adherence to share lock-up periods for major shareholders and executives, ensuring stability in shareholding[117]. - There are no significant lawsuits or arbitration matters during the reporting period[124].

浙江东方基因生物制品股份有限公司 2024 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688298 证券简称：东方生物 公告编号：2024-046 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 经中国证券监督管理委员会证监许可[2019]2999 号文同意，浙江东方基因生物 制品股份有限公司（以下简称"公司"或"东方生物"）首次公开发行人民币普通股 （A 股）30,000,000 股，每股发行价格为 21.25 元，募集资金总额 637,500,000.00 元，募集资金净额为人民币 550,817,900.26 元。以上募集资金业经立信会计师事务 所（特殊普通合伙）验资，并由其出具信会师报字（2020）第 ZF10018 号验资报告。 （二）2024 年半年度募集资金使用情况及结余情况 截至 2024 年 6 月 30 日，本公司募集资金实际使用情况为：公司首发募集资金净 额 550,817,900.26 元，本年度募投项目投入额 7,987,7 ...

证券代码：688298 证券简称：东方生物 公告编号：2024-050 浙江东方基因生物制品股份有限公司 关于召开 2024 年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024 年第二次临时股东大会 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 9 月 20 日 至 2024 年 9 月 20 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 股东大会召开日期：2024年9月20日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （四） 现场会议召开的日期、 ...

证券代码：688298 证券简称：东方生物 公告编号：2024-051 浙江东方基因生物制品股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 09 月 05 日(星期四) 上午 11:00-12:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.s seinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 08 月 29 日(星期四) 至 09 月 04 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zqb@orientg ene.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 浙江东方基因生物制品股份有限公司（以下简称"公司"）已于 2024 年 8 月 30 日发布公司 2024 年半年度报告，为便于广大投资者更全面深入地了解公司 2024 年半年度经营成果、财务状况，公司计划于 2024 年 ...

证券代码：688298 证券简称：东方生物 公告编号：2024-045 浙江东方基因生物制品股份有限公司 关于以集中竞价交易方式回购股份进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/8，由实际控制人方剑秋先生、方效良先生、 | | --- | --- | | | 方炳良先生提议 | | 回购方案实施期限 | 2024/2/7~2025/2/6 | | 预计回购金额 | 万元 25,000 万元~30,000 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 833.27 万股 | | 累计已回购股数占总股本比例 | 4.13% | | 累计已回购金额 | 2.75 亿元 | | 实际回购价格区间 | 27.83 元/股~34.50 元/股 | 特此公告。 浙江东方基因生物制品股份有限公司董事会 一、 回购股份的基本情况 浙江东方基因生物制 ...

证券代码：688298 证券简称：东方生物 公告编号：2024-044 浙江东方基因生物制品股份有限公司 关于以集中竞价交易方式回购股份进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/8，由实际控制人方剑秋先生、方炳良先 | | --- | --- | | | 生、方效良先生提议 | | 回购方案实施期限 | 2024/2/7~2025/2/6 | | 预计回购金额 | 万元 25,000 万元~30,000 | | 回购用途 | □减少注册资本 | | | √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 833.27 万股 | | 累计已回购股数占总股本比例 | 4.13% | | 累计已回购金额 | 2.75 亿元 | | 实际回购价格区间 | 27.83 元/股~34.50 元/股 | 一、 回购股份的基本情况 人民币 20,000.00 万元（含），即将回购资金总额由 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司的全资子公司美国衡健生物科技有限公 司（简称"美国衡健"或"公司"）近日取得由U.S. Food & Drug Administration （美国食品药品监督管理局，以下简称"FDA"）批准的Healgen COVID-19/Flu A&B Ag Combo Rapid Test Cassette (Swab)的紧急使用授权（EUA），相关公告如下： 一、医疗器械注册证的基本情况 | 产品名称 | 证书 | 预期 | 授权 | | --- | --- | --- | --- | | | 编号 | 用途 本产品获准Point of Care(POC)专 | 日期 | | Healgen COVID-19/Flu A&B Ag Combo Rapid Test Cassette (Swab) Healgen新冠、甲乙流抗原快速联合 | EUA240010 | 业使用，适用于感染症状出现的5天 内，通过前鼻拭子采集的样本快速 | 2024/6/10 ...

浙江东方基因生物制品股份有限公司 关于以集中竞价交易方式回购股份进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688298 证券简称：东方生物 公告编号：2024-042 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定"在回购股份期间,上市公司应当在每个月的前三个 交易日内，公告截至上月末的回购进展情况"，现将公司回购股份进展情况公告如 下： 公司自 2024 年 5 月开始实施回购，截至 2024 年 5 月 31 日，公司通过上海证 券交易所系统以集中竞价交易方式回购公司股份累计达到 833.27 万股，占公司总 股本 20,160.00 万股的比例为 4.13%，回购成交的最低价为 27.83 元/股，最高价为 34.50 元/股，累计支付总金额为 2.75 亿元。 三、 其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出回 购 ...

证券代码：688298 证券简称：东方生物 公告编号：2024-041 浙江东方基因生物制品股份有限公司 重要内容提示： | 回购方案首次披露日 | 2024/2/8，由实际控制人方剑秋先生、方炳良先生、 | | --- | --- | | | 方效良先生提议 | | 回购方案实施期限 | 2024/2/7~2025/2/6 | | 预计回购金额 | 25,000 万元~30,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 万股 806.72 | | 累计已回购股数占总股本比例 | 4.00% | | 累计已回购金额 | 亿元 2.67 | | 实际回购价格区间 | 28.33 元/股~34.50 元/股 | 一、 回购股份的基本情况 浙江东方基因生物制品股份有限公司（以下简称"公司"）于 2024 年 2 月 7 日召开第三届董事会第六次会议，审议通过了《关于以集中竞价交易方式回购股 份方案的议案》，同意公司以自有资金或自筹资金通过上海证券交易所交易系统以 集中竞价交易方式 ...

地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 国浩律师（杭州）事务所 关 于 浙江东方基因生物制品股份有限公司 2023 年年度股东大会 法律意见书 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二〇二四年五月 国浩律师（杭州）事务所 法律意见书 国浩律师（杭州）事务所 关 于 浙江东方基因生物制品股份有限公司 2023 年年度股东大会 法律意见书 为出具本法律意见书，本所律师出席了公司本次股东大会，审查了公司提供 的本次股东大会的有关文件的原件及复印件，包括但不限于公司召开本次股东大 会的各项议程及相关决议等文件，同时听取了公司就有关事实的陈述和 ...